Valuation: Healios K.K.

Market Cap 35.24B 218M 191M 176M 163M 308M 20.81B 314M 2.1B 826M 10.25B 819M 801M P/E 2026 *
-7.17x
P/E 2027 * -12.7x
Enterprise Value 34.98B 217M 189M 175M 161M 306M 20.65B 311M 2.09B 820M 10.17B 813M 795M EV / Sales 2026 *
58.1x
EV / Sales 2027 * 4.02x
Free-Float
77.9%
Yield 2026 *
-
Yield 2027 * -
1 day+1.95%
1 week+2.35%
Current month+3.16%
1 month-9.69%
3 months-28.10%
6 months-4.40%
Current year-4.74%
1 week 235
Extreme 235
268
1 month 234
Extreme 234
281
Current year 234
Extreme 234
483
1 year 234
Extreme 234
747
3 years 114
Extreme 114
747
5 years 114
Extreme 114
2,557
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 2018-02-28
Director of Finance/CFO 49 2019-07-15
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 49 2012-01-31
Director/Board Member 49 2018-02-28
Director/Board Member 72 2018-02-28
Change 5-day change 1-year change 3-year change Capi.($)
+1.95%+2.35%-48.52%-9.69% 213M
-4.14%-7.44%+64.26%+119.36% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-2.98%+2.74%+18.56%+461.76% 25.63B
-0.52%-2.40%-19.53%-14.67% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
+0.88%+2.00%+25.39%+197.01% 14.35B
Average -0.50%+1.09%+44.83%+130.12% 24.24B
Weighted average by Cap. -1.11%+0.29%+56.46%+137.96%

Financials

2026 *2027 *
Net sales 602M 3.73M 3.26M 3.01M 2.78M 5.27M 356M 5.36M 35.94M 14.11M 175M 14M 13.69M 9.12B 56.45M 49.38M 45.55M 42.07M 79.82M 5.38B 81.16M 544M 214M 2.65B 212M 207M
Net income -4.77B -29.54M -25.84M -23.83M -22.01M -41.76M -2.82B -42.47M -285M -112M -1.39B -111M -108M -2.94B -18.23M -15.95M -14.71M -13.59M -25.78M -1.74B -26.21M -176M -69.02M -857M -68.45M -66.96M
Net Debt -260M -1.61M -1.41M -1.3M -1.2M -2.27M -153M -2.31M -15.51M -6.09M -75.57M -6.04M -5.91M 1.46B 9.06M 7.92M 7.31M 6.75M 12.81M 864M 13.02M 87.32M 34.29M 426M 34.01M 33.27M
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
26-07-10 JP¥261.00 +1.95% 2,199,900
26-07-09 JP¥256.00 +7.56% 2,560,200
26-07-08 JP¥238.00 -1.24% 1,250,700
26-07-07 JP¥241.00 -4.37% 2,146,000
26-07-06 JP¥252.00 +0.80% 772,400
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
261.00JPY
Average target price
779.83JPY
Spread / Average Target
+198.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4593 Stock